Brief: Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
09/05/2024 15:49
May 9 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS ANNOUNCES FIRST LUPUS PATIENT TREATED IN
PHASE
1 AUTOIMMUNITY STUDY OF OFF-THE-SHELF FT819 CAR T-CELL PROGRAM
Source text for Eikon: ID:nGNXbr3w61
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview